Experimental combo therapy for advanced breast cancer tested in small early trial
Disease control
Terminated
This early-phase study tested a new treatment for people with advanced breast cancer that had stopped responding to standard therapies. The treatment combined a patient's own engineered immune cells (CLBR001) with an antibody drug (ABBV-461). The study aimed to find the safest do…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 05, 2026 12:08 UTC